Sunday, September 27, 2026

Catalyst Pharmaceuticals Stock Over 2% Down At Session Start On Friday

ViaNews Editorial Team

December 18, 2020

Catalyst Pharmaceuticals Stock Over 2% Down At Session Start On Friday

Shares of Catalyst Pharmaceuticals slid 2.72% to $3.58 at 09:42 EST on Friday, after two successive sessions in a row of losses. The Nasdaq Stock Market is jumping 0.84% to $12,764.80, after four successive sessions in a row of gains. This seems, up until now, a somewhat positive trend exchanging session today.

Catalyst Pharmaceuticals's last close was $3.79, 47.49% under its 52-week high of $5.28.

Catalyst Pharmaceuticals's Sales

Catalyst Pharmaceuticals's sales growth is 11.6% for the current quarter and 4.6% for the next. The company's growth estimates for the ongoing quarter is 25% and a drop 10% for the next.

Catalyst Pharmaceuticals's Revenue

Year-on-year quarterly revenue growth declined by 5.1%, now sitting on 118.18M for the twelve trailing months.

Catalyst Pharmaceuticals's Stock Yearly Top and Bottom Value

Catalyst Pharmaceuticals's stock is valued at $3.58 at 09:42 EST, way below its 52-week high of $5.28 and way above its 52-week low of $2.55.

Catalyst Pharmaceuticals's Moving Average

Catalyst Pharmaceuticals's value is above its 50-day moving average of $3.42 and under its 200-day moving average of $3.79.

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Enterprise AI Agents Scale Up Through Partnerships and Funding, But Data Readiness Lags Ambition
A wave of vertical AI-agent startups (Swarm, Veridox, Avallon AI, DA2, F2, Earthian, Meanwhile, Covecta, Penguin AI, Maisa AI) is being funded and profiled just as major infrastructure players — Microsoft/Mistral, Siemens/NVIDIA, and Manulife/Microsoft — cement enterprise AI governance and compute partnerships. Yet a Google Cloud report shows AI agents still lack access to the majority of company data (only 45% on average), and insider selling at incumbent C3.ai signals investor caution even as adoption intent (100% planned agentic AI use within two years) races ahead of actual data infrastructure.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Berkshire Hathaway
Both facts report Berkshire Hathaway's cash position on 2026-01-01 with identical observation timestamps, but claim vastly different values: 380 billion USD vs 400 USD. These cannot both be true for the same entity at the same point in time. The magnitude of the discrepancy (a factor of ~10^9) rules out rounding, unit conversion, or methodological differences.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,984
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,984 facts checked against source5,306 source documents archived
Query this data → isubstrate.com